

# Olufunmilayo I Olopade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7150594/publications.pdf>

Version: 2024-02-01

242  
papers

17,780  
citations

17429

63  
h-index

17090

122  
g-index

254  
all docs

254  
docs citations

254  
times ranked

23258  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	13.5	1,485
2	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 967.	3.8	1,241
3	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
4	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 1055-1062.	0.8	1,095
5	Wnt/ $\beta$ -Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome. <i>American Journal of Pathology</i> , 2010, 176, 2911-2920.	1.9	450
6	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. <i>Nature Reviews Cancer</i> , 2007, 7, 937-948.	12.8	400
7	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
8	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
9	Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4515-4521.	0.8	341
10	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
11	Assembly of a pan-genome from deep sequencing of 910 humans of African descent. <i>Nature Genetics</i> , 2019, 51, 30-35.	9.4	276
12	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	0.8	270
13	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
14	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>American Journal of Human Genetics</i> , 2008, 82, 937-948.	2.6	257
15	A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 221-238.	157.7	252
16	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
17	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
18	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 703-711.	1.1	223

#	ARTICLE	IF	CITATIONS
19	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
20	Targeting Health Disparities: A Model Linking Upstream Determinants To Downstream Interventions. <i>Health Affairs</i> , 2008, 27, 339-349.	2.5	220
21	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1925.	3.8	219
22	RAD51 135Gâ†C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	2.6	217
23	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. <i>JAMA Oncology</i> , 2017, 3, 1654.	3.4	208
24	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	9.4	184
25	Advances in Breast Cancer: Pathways to Personalized Medicine. <i>Clinical Cancer Research</i> , 2008, 14, 7988-7999.	3.2	165
26	Breast cancer genetics in African Americans. <i>Cancer</i> , 2003, 97, 236-245.	2.0	153
27	Disparities in Genetic Testing: Thinking Outside the BRCA Box. <i>Journal of Clinical Oncology</i> , 2006, 24, 2197-2203.	0.8	152
28	Î²-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0117097.	1.1	146
29	A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. <i>Nature Communications</i> , 2016, 7, 12522.	5.8	136
30	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapyâ€related leukemia. <i>Cancer</i> , 2016, 122, 304-311.	2.0	129
31	Epidemiology of Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 8-16.	1.0	126
32	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
33	HIF-2Î± promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 256.	3.5	124
34	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
35	Association of Event-Free and Distant Recurrenceâ€Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
36	Inherited predisposition to breast cancer among African American women. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 31-39.	1.1	116

#	ARTICLE	IF	CITATIONS
37	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. <i>Nature Communications</i> , 2021, 12, 4423.	5.8	111
38	Effect of Oophorectomy on Survival After Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA Oncology</i> , 2015, 1, 306.	3.4	107
39	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 176-182.	3.0	104
40	Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both <i>t(14;18)(q32;q21)</i> and <i>t(8;14)(q24;q32)</i> or <i>t(8;22)(q24;q11)</i> . <i>Genes Chromosomes and Cancer</i> , 1990, 2, 147-158.	1.5	103
41	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations among clinic-based African American families with breast cancer. <i>Human Genetics</i> , 2000, 107, 186-191.	1.8	103
42	The Breast–Thyroid Cancer Link: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 231-238.	1.1	103
43	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
44	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
45	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
46	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
47	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
48	High prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in unselected Nigerian breast cancer patients. <i>International Journal of Cancer</i> , 2012, 131, 1114-1123.	2.3	81
49	Inherited Breast Cancer in Nigerian Women. <i>Journal of Clinical Oncology</i> , 2018, 36, 2820-2825.	0.8	80
50	Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1345-1358.	4.2	80
51	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. <i>Genetics in Medicine</i> , 2015, 17, 485-492.	1.1	79
52	Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: Feature selection. <i>Medical Physics</i> , 2000, 27, 4-12.	1.6	78
53	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
54	<i>BRCA2</i> Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	3.0	77

#	ARTICLE	IF	CITATIONS
55	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. <i>Nature Communications</i> , 2018, 9, 4181.	5.8	77
56	Confronting Genetic Testing Disparities. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1783.	3.8	76
57	Genetic and functional analysis of <i>CHEK2</i> ( <i>CHK2</i> ) variants in multiethnic cohorts. <i>International Journal of Cancer</i> , 2007, 121, 2661-2667.	2.3	75
58	FANCF methylation contributes to chemoselectivity in ovarian cancer. <i>Cancer Cell</i> , 2003, 3, 417-420.	7.7	72
59	Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. <i>Nature Communications</i> , 2019, 10, 880.	5.8	71
60	A genome-wide association study of breast cancer in women of African ancestry. <i>Human Genetics</i> , 2013, 132, 39-48.	1.8	70
61	Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients. <i>Oncotarget</i> , 2016, 7, 55231-55248.	0.8	70
62	Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. <i>Cancer Research</i> , 2002, 62, 1481-8.	0.4	70
63	Naturally occurring <i>BRCA2</i> alternative mRNA splicing events in clinically relevant samples. <i>Journal of Medical Genetics</i> , 2016, 53, 548-558.	1.5	69
64	Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 873-885.	1.9	69
65	Building capacity for sustainable research programmes for cancer in Africa. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 251-259.	12.5	68
66	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. <i>Carcinogenesis</i> , 2012, 33, 835-840.	1.3	64
67	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. <i>Npj Breast Cancer</i> , 2017, 3, 31.	2.3	64
68	Efficacy of Risk-Reducing Salpingo-Oophorectomy in Women with BRCA-1 and BRCA-2 Mutations. <i>Breast Journal</i> , 2004, 10, S5-S9.	0.4	63
69	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	2.2	57
70	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
71	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. <i>Human Molecular Genetics</i> , 2016, 25, ddw305.	1.4	50
72	Codeletion of <i>CDKN2</i> and <i>MTAP</i> genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 72-78.	1.5	49

#	ARTICLE	IF	CITATIONS
73	Obesity and Height in Urban Nigerian Women with Breast Cancer. <i>Annals of Epidemiology</i> , 2003, 13, 455-461.	0.9	49
74	β-catenin regulates <i>c-Myc</i> and <i>CDKN1A</i> expression in breast cancer cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 431-439.	1.3	48
75	Radiogenomics of breast cancer using dynamic contrast enhanced MRI and gene expression profiling. <i>Cancer Imaging</i> , 2019, 19, 48.	1.2	48
76	Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 394-405.	0.4	48
77	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
78	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
79	Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. <i>Gastroenterology</i> , 2015, 149, 1446-1453.	0.6	46
80	Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: ?2-glycoprotein I antibodies as a marker of response to therapy. , 1999, 14, 171-176.		45
81	Building local capacity for genomics research in Africa: recommendations from analysis of publications in Sub-Saharan Africa from 2004 to 2013. <i>Global Health Action</i> , 2016, 9, 31026.	0.7	45
82	Relationships between computer-extracted mammographic texture pattern features and <i>BRCA1/2</i> mutation status: a cross-sectional study. <i>Breast Cancer Research</i> , 2014, 16, 424.	2.2	44
83	A functionally significant SNP in <i>TP53</i> and breast cancer risk in African-American women. <i>Npj Breast Cancer</i> , 2017, 3, 5.	2.3	44
84	Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in <i>BRCA1</i> Mutation Carriers. <i>Clinical Cancer Research</i> , 2019, 25, 1786-1794.	3.2	44
85	Prediction of <i>BRCA</i> Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. <i>Journal of Clinical Oncology</i> , 2009, 27, 1184-1190.	0.8	43
86	Alcohol Consumption and Breast Cancer Risk among Women in Three Sub-Saharan African Countries. <i>PLoS ONE</i> , 2014, 9, e106908.	1.1	43
87	Recurrent <i>BRCA1</i> and <i>BRCA2</i> mutations in breast cancer patients of African ancestry. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 889-894.	1.1	42
88	Effect of stove intervention on household air pollution and the respiratory health of women and children in rural Nigeria. <i>Air Quality, Atmosphere and Health</i> , 2013, 6, 553-561.	1.5	42
89	A comprehensive examination of breast cancer risk loci in African American women. <i>Human Molecular Genetics</i> , 2014, 23, 5518-5526.	1.4	42
90	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42

#	ARTICLE	IF	CITATIONS
91	Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 703-712.	1.1	42
92	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1168-1176.	3.0	41
93	Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2016, 11, e0147145.	1.1	41
94	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
95	Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models. <i>Cancer Research</i> , 2014, 74, 7406-7417.	0.4	37
96	Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 359-367.	1.1	36
97	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. <i>Journal of the National Cancer Institute</i> , 2018, 110, 985-993.	3.0	35
98	Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study. <i>Lancet Haematology</i> , 2020, 7, e534-e540.	2.2	35
99	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. <i>Human Mutation</i> , 2019, 40, e1-e23.	1.1	34
100	Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. <i>Human Genetics</i> , 2016, 135, 1145-1159.	1.8	32
101	Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. <i>Breast Cancer Research</i> , 2019, 21, 3.	2.2	32
102	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
103	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
104	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
105	Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. <i>JAMA Oncology</i> , 2017, 3, 928.	3.4	28
106	The <i>FANCM:p.Arg658*</i> truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
107	Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?. <i>Cancer</i> , 2019, 125, 213-222.	2.0	28
108	Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. <i>Breast Cancer Research</i> , 2021, 23, 18.	2.2	27



#	ARTICLE	IF	CITATIONS
109	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
110	LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. <i>Scientific Reports</i> , 2018, 8, 15572.	1.6	26
111	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2018, 8, 156.	1.3	26
112	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. <i>Human Mutation</i> , 2019, 40, 1781-1796.	1.1	26
113	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 561-571.	1.1	25
114	Household air pollution and chronic hypoxia in the placenta of pregnant Nigerian women: A randomized controlled ethanol Cookstove intervention. <i>Science of the Total Environment</i> , 2018, 619-620, 212-220.	3.9	25
115	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 398-403.	2.9	25
116	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 841-849.	1.1	25
117	Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1016-1026.	1.1	24
118	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. <i>Nature Communications</i> , 2021, 12, 4198.	5.8	24
119	Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 440-449.	0.4	23
120	Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. <i>Journal of Global Oncology</i> , 2017, 3, 194-200.	0.5	23
121	Population-dependent Intron Retention and DNA Methylation in Breast Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 461-469.	1.5	23
122	Mutations in context: implications of BRCA testing in diverse populations. <i>Familial Cancer</i> , 2018, 17, 471-483.	0.9	23
123	<i>CDKN2A</i> Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1364-1370.	1.1	23
124	Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. <i>Cancer</i> , 2020, 126, 4013-4022.	2.0	23
125	The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. <i>Cancer</i> , 2021, 127, 4072-4080.	2.0	23
126	Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0165559.	1.1	23



#	ARTICLE	IF	CITATIONS
127	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
128	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. <i>Targeted Oncology</i> , 2015, 10, 501-508.	1.7	22
129	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
130	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. <i>Nature Communications</i> , 2021, 12, 6946.	5.8	22
131	Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers. <i>Medical Physics</i> , 2014, 41, 031917.	1.6	21
132	Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. <i>Breast</i> , 2015, 24, 131-136.	0.9	21
133	Relationships between computer-extracted mammographic texture pattern features and. <i>Breast Cancer Research</i> , 2014, 16, 424.	2.2	21
134	Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. <i>Scientific Reports</i> , 2022, 12, 4190.	1.6	21
135	<i>CDKN2</i> gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 865-870.	1.2	20
136	Infrastructural Challenges Lead to Delay of Curative Radiotherapy in Nigeria. <i>JCO Global Oncology</i> , 2020, 6, 269-276.	0.8	20
137	The global role, impact, and limitations of Community Health Workers (CHWs) in breast cancer screening: a scoping review and recommendations to promote health equity for all. <i>Global Health Action</i> , 2021, 14, 1883336.	0.7	20
138	Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. <i>PLoS ONE</i> , 2015, 10, e0142224.	1.1	20
139	Race, Ethnicity, and the Diagnosis of Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 141.	3.8	19
140	Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. <i>Cell Death and Disease</i> , 2019, 10, 666.	2.7	19
141	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
142	A case-only study to identify genetic modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
143	Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. <i>Cancer</i> , 2021, 127, 1827-1835.	2.0	19
144	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19

#	ARTICLE	IF	CITATIONS
145	Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. , 2000, 28, 164-172.		18
146	Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change. <i>Journal of Clinical Oncology</i> , 2006, 24, 2135-2136.	0.8	18
147	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
148	Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. <i>Cancer Prevention Research</i> , 2017, 10, 255-266.	0.7	18
149	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
150	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. <i>American Journal of Human Genetics</i> , 2021, 108, 564-582.	2.6	18
151	Race, the microbiome and colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 773-787.	0.8	18
152	Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. <i>Familial Cancer</i> , 2018, 17, 495-505.	0.9	17
153	Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 93.	1.2	17
154	Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 636-643.	1.1	16
155	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. <i>International Journal of Cancer</i> , 2019, 145, 3321-3333.	2.3	16
156	Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. <i>Clinical Genetics</i> , 2019, 95, 293-301.	1.0	16
157	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
158	Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. <i>Science of the Total Environment</i> , 2017, 599-600, 2175-2181.	3.9	14
159	Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. <i>PLoS Genetics</i> , 2017, 13, e1006727.	1.5	14
160	PREVALENCE AND AETIOLOGY OF BACTEREMIA IN FEBRILE CHILDREN WITH SICKLE CELL DISEASE AT A NIGERIAN TERTIARY HOSPITAL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017039.	0.5	13
161	Global disparities in breast cancer outcomes: new perspectives, widening inequities, unanswered questions. <i>The Lancet Global Health</i> , 2020, 8, e978-e979.	2.9	13
162	Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities. <i>Cancer Cell</i> , 2021, 39, 730-733.	7.7	13

#	ARTICLE	IF	CITATIONS
163	Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk.. Journal of Clinical Oncology, 2020, 38, 1506-1506.	0.8	13
164	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	1.1	12
165	Relationships between Plasma Micronutrients, Serum IgE, and Skin Test Reactivity and Asthma among School Children in Rural Southwest Nigeria. Journal of Biomarkers, 2014, 2014, 1-9.	1.0	11
166	Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer, 2015, 121, 2237-2243.	2.0	11
167	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment, 2016, 160, 121-129.	1.1	11
168	Genetic anticipation in <i>BRCA1/BRCA2</i> families after controlling for ascertainment bias and cohort effect. Cancer, 2016, 122, 1913-1920.	2.0	11
169	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	0.9	11
170	Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. International Journal of Cancer, 2018, 142, 36-43.	2.3	11
171	Implementing oncology clinical trials in Nigeria: a model for capacity building. BMC Health Services Research, 2020, 20, 713.	0.9	11
172	Addressing health disparities in cancer with genomics. Nature Reviews Genetics, 2021, 22, 621-622.	7.7	11
173	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Human Molecular Genetics, 2022, 31, 3133-3143.	1.4	11
174	An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. Journal of Racial and Ethnic Health Disparities, 2017, 4, 140-148.	1.8	10
175	LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women. Breast Cancer: Targets and Therapy, 2019, Volume 11, 1-12.	1.0	10
176	Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10
177	Hematologic toxicity in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Medicine, 2019, 8, 5609-5618.	1.3	10
178	The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. Journal of Clinical Oncology, 2019, 37, 2177-2178.	0.8	10
179	Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study. Journal of Cancer Education, 2019, 34, 50-55.	0.6	10
180	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	0.6	10

#	ARTICLE	IF	CITATIONS
181	USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. <i>JAMA Network Open</i> , 2019, 2, e1910142.	2.8	9
182	Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. <i>Annals of Surgical Oncology</i> , 2022, 29, 1423-1432.	0.7	9
183	Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1341-1348.	1.9	8
184	Breast Cancer Risk-Associated SNPs in the <i>mTOR</i> Promoter Form <i>De Novo</i> KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. <i>Molecular Cancer Research</i> , 2019, 17, 2244-2256.	1.5	8
185	p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. <i>Nature Communications</i> , 2020, 11, 5007.	5.8	8
186	Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
187	N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 106-113.	0.7	7
188	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 639-648.	1.1	7
189	A Preliminary Study of the Suitability of Archival Bone Marrow and Peripheral Blood Smears for Diagnosis of CML Using FISH. <i>Advances in Hematology</i> , 2014, 2014, 1-5.	0.6	6
190	Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. <i>Molecular Carcinogenesis</i> , 2018, 57, 1311-1318.	1.3	6
191	Black Lives Matter Worldwide: Retooling Precision Oncology for True Equity of Cancer Care. <i>Cell Reports Medicine</i> , 2020, 1, 100079.	3.3	6
192	Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 243-250.	1.1	6
193	The <i>BRCA1</i> Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. <i>Cancer Research</i> , 2021, 81, 1540-1551.	0.4	6
194	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2038-2043.	1.1	6
195	Breast cancer surveillance in high-risk women with magnetic resonance imaging every 6 months.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1506.	0.8	6
196	Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. <i>PLoS ONE</i> , 2022, 17, e0268693.	1.1	6
197	Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete Radiologic Response to Neoadjuvant Paclitaxel: A Case Report. <i>Clinical Breast Cancer</i> , 2015, 15, e155-e158.	1.1	5
198	Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. <i>Journal of Genetic Counseling</i> , 2018, 27, 863-873.	0.9	5

#	ARTICLE	IF	CITATIONS
199	Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 116-118.	1.1	5
200	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
201	Breast Cancer Knowledge Assessment of Health Workers in Ibadan, Southwest Nigeria. <i>JCO Global Oncology</i> , 2020, 6, 387-394.	0.8	5
202	Formal Assessment of Teamwork Among Cancer Health Care Professionals in Three Large Tertiary Centers in Nigeria. <i>JCO Global Oncology</i> , 2020, 6, 560-568.	0.8	5
203	Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 515-523.	1.1	5
204	Assessment of Breast Cancer Management in Sub-Saharan Africa. <i>JCO Global Oncology</i> , 2021, 7, 1593-1601.	0.8	5
205	Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 485-494.	1.1	5
206	Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. <i>Cancer Cell</i> , 2018, 34, 529-530.	7.7	4
207	Magnetic resonance angiography reveals increased arterial blood supply and tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer. <i>NMR in Biomedicine</i> , 2020, 33, e4363.	1.6	4
208	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. <i>Genetics in Medicine</i> , 2020, 22, 1401-1406.	1.1	4
209	Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. <i>Physica Medica</i> , 2021, 81, 31-39.	0.4	4
210	Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. <i>Clinical Breast Cancer</i> , 2016, 16, e61-e63.	1.1	3
211	Ancestrally unbiased polygenic breast cancer (BC) risk assessment.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10502-10502.	0.8	3
212	Doing better and being better in breast cancer care: an interview with Funmi Olopade. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	3
213	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
214	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
215	Feasibility of genetic testing for cancer risk assessment programme in Nigeria. <i>Ecancermedicalscience</i> , 2021, 15, 1283.	0.6	2
216	Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 72-78.	1.5	2

#	ARTICLE	IF	CITATIONS
217	Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemaciclib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer. <i>Cancer Research</i> , 2022, 82, OT1-10-02-OT1-10-02.	0.4	2
218	Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 27-35.	0.6	1
219	Pre- and post-treatment body weight and prognosis in a multiethnic cohort of breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1501-1501.	0.8	1
220	Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry. , 2020, , .		1
221	Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry. , 2020, , .		1
222	Associations between age of menarche and genetic variation in women of African descent: genome-wide association study and polygenic score analysis. <i>Journal of Epidemiology and Community Health</i> , 2021, , jech-2020-216000.	2.0	1
223	THE EFFECT OF ALPHA THALASSEMIA, HbF and HbC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022001.	0.5	1
224	A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries.. <i>Journal of Clinical Oncology</i> , 2022, 40, 557-557.	0.8	1
225	Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screeningâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 883.	3.4	0
226	Reply to Q. Chu et al. <i>JCO Global Oncology</i> , 2021, 7, 185-186.	0.8	0
227	Breast Cancer Research to Support Evidence-Based Medicine in Nigeria: A Review of the Literature. <i>JCO Global Oncology</i> , 2021, 7, 384-390.	0.8	0
228	Validation of the RSclin risk calculator using the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2021, 39, 549-549.	0.8	0
229	Abstract 879: Validation of the Nigerian Breast Cancer Study model for predicting individual breast cancer risk in Cameroon and Uganda. , 2021, , .		0
230	Neoadjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): Efficacy and safety in a phase II feasibility study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11554-e11554.	0.8	0
231	Extended follow-up in the COGENT study: A randomized study of in-person versus telephone disclosure of cancer genetic test results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1504-1504.	0.8	0
232	Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13015-e13015.	0.8	0
233	Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12106-e12106.	0.8	0
234	Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3084-3084.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Survey of medical student knowledge in oncology and survivorship care in Nigeria: A pilot study.. Journal of Clinical Oncology, 2019, 37, e18106-e18106.	0.8	0
236	ASO Visual Abstract: Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Annals of Surgical Oncology, 2022, 29, 1435-1436.	0.7	0
237	Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Global Oncology, 2022, , .	0.8	0
238	Innovative Strategies for Developing Biomarker-Informed Cancer Clinical Trials to Accelerate Progress in Precision Oncology in Sub-Saharan Africa. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 438-446.	1.8	0
239	Racial differences in interest and use of integrative medicine among patients with breast cancer.. Journal of Clinical Oncology, 2022, 40, 12101-12101.	0.8	0
240	Adapting a medical school cancer research education program to the virtual environment.. Journal of Clinical Oncology, 2022, 40, 11029-11029.	0.8	0
241	Real-world evidence on predictors of survival for hormone-positive and triple-negative advanced breast cancer by treatment and <i>BRCA</i> status in the United States.. Journal of Clinical Oncology, 2022, 40, e18754-e18754.	0.8	0
242	Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).. Journal of Clinical Oncology, 2022, 40, TPS622-TPS622.	0.8	0